Liquidia Corp anticipates significant revenue growth ahead of Q1 earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2026
0mins
Source: NASDAQ.COM
Liquidia Corp's stock surged by 14.99% as it reached a 52-week high, reflecting strong investor interest.
The company is set to announce its Q1 earnings on May 11, with a consensus EPS estimate of $0.41, indicating a substantial year-over-year increase of 191.1%. Additionally, anticipated revenue for Q1 is projected at $116.59 million, showcasing a staggering year-over-year growth of 3636.9%, driven by strong demand for its inhaled drug YUTREPIA. This positive outlook comes despite previous volatility in meeting EPS estimates, suggesting a potential turnaround in profitability.
The upcoming earnings report is expected to further solidify Liquidia's position in the biopharmaceutical market, especially with its YUTREPIA product capturing a significant market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to fall
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 68.650
Low
31.00
Averages
47.50
High
67.00
Current: 68.650
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Achieves Major Regulatory Milestone for Gene Therapy
- Stock Surge: uniQure's shares soared 78.4% on June 17 following the announcement of a major regulatory milestone for AMT-130, although a 3.9% drop on June 18 indicates some volatility; overall, investor confidence in the therapy appears to be strengthening.
- FDA Meeting Outcomes: During a recent Type B meeting, the FDA confirmed that three-year data from the AMT-130 study could serve as the primary basis for a Biologics License Application (BLA), which is expected to be filed in Q3 2026, potentially accelerating market access for the therapy.
- Clinical Trial Design Adjustments: The FDA has requested that uniQure align on the confirmatory study design before BLA submission, including the consideration of a standard-of-care control group, which will impact future clinical trial strategies and timelines.
- Significant Market Potential: As the first therapy for Huntington's disease to receive FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, AMT-130's potential approval could significantly enhance uniQure's market position, addressing a substantial unmet need in Huntington's disease treatment and presenting considerable commercial opportunities for the company.
See More
Beam Therapeutics Receives FDA Clearance for Gene-Editing Therapy
- FDA Approval Milestone: Beam Therapeutics received FDA clearance for its BEAM-304 gene-editing therapy, marking a significant advancement in the liver-targeted genetic disease space, which is expected to enhance its competitiveness in the rare disease market.
- Significant Treatment Potential: BEAM-304 aims to correct mutations in the PAH gene responsible for phenylketonuria (PKU) by lowering toxic phenylalanine levels, potentially allowing patients to maintain a normal diet and reducing reliance on specialized medical foods, which could have a profound market impact.
- Clinical Trial Plans: Beam plans to conduct a Phase I/II open-label clinical study in PKU patients to assess the safety and tolerability of BEAM-304, which is expected to provide critical data for the clinical application of gene-editing therapies and drive future treatment options.
- Strong Stock Performance: Year-to-date, Beam Therapeutics' stock has risen 23.2%, significantly outperforming the biotechnology sector, reflecting positive market expectations for its new therapy and increased investor confidence.
See More
Mirum and Incyte Report Positive Results for FOP Study
- Clinical Trial Results: Mirum and Incyte's Phase II PROGRESS study of zilurgisertib showed that only 3.1% of patients developed new lesions compared to 16.7% in the placebo group, achieving an 81% reduction, indicating the drug's potential in treating this ultra-rare disease.
- Sustained Efficacy: In the open-label extension phase, no new lesions were observed among patients continuing zilurgisertib treatment at 48 weeks, with total lesion volume continuing to decline, demonstrating the drug's long-term efficacy and safety, addressing the urgent need for effective treatments.
- FDA Priority Review: Following positive clinical data, the FDA has accepted the NDA for zilurgisertib and granted Priority Review status, with a decision expected by September 26, 2026, which will expedite the drug's market entry to meet the demand for new therapies.
- Market Performance: Year-to-date, shares of Mirum and Incyte have risen by 28.5% and 1%, respectively, against a 1.4% decline in the biotech sector, reflecting investor optimism regarding their clinical advancements and enhancing their competitive position in the market.
See More
Liquidia Corp Stock Surpasses Analyst Target Price
- Stock Performance: Liquidia Corp's shares recently rose to $71.72, surpassing the average analyst 12-month target price of $66.12, indicating increased market confidence and potentially attracting more investor interest.
- Analyst Reactions: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target; currently, Liquidia's target prices range from $59.00 to $75.00, reflecting varying expectations about the company's future performance.
- Market Signal: The stock's breach of the target price provides a strong signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it’s time to take profits to mitigate risk.
- Analyst Ratings: The average rating for Liquidia Corp within the Zacks coverage universe ranges from 1 to 5, with 1 being a Strong Buy and 5 a Strong Sell, highlighting the differing opinions among analysts regarding the company's future outlook.
See More
Liquidia Presents Research at PHA 2026 Conference
- Research Presentation: Liquidia will present four posters at the 2026 PHA International Conference, highlighting patient-reported cough outcomes from the ASCENT study of YUTREPIA®, demonstrating the company's commitment to pulmonary hypertension patients.
- Patient Feedback Analysis: The posters will showcase cough outcomes in patients with pulmonary hypertension associated with interstitial lung disease over 24 weeks of treatment, providing insights that could influence future treatment strategies.
- Care Team Role Exploration: Liquidia will also discuss the role of pharmacists within pulmonary hypertension care teams and the mental health challenges faced by caregivers, aiming to enhance support for patients and their families.
- Safety and Efficacy Data Review: The company will reiterate safety and exploratory efficacy data from the ASCENT study, further solidifying the potential application of YUTREPIA® in treating pulmonary hypertension.
See More
Liquidia Corporation to Join S&P SmallCap 600 Index
- Index Inclusion Milestone: Liquidia Corporation announced its inclusion in the S&P SmallCap 600 Index effective June 22, 2026, marking a significant advancement in market capitalization, liquidity, and profitability, which is expected to enhance its visibility and attractiveness among investors.
- Positive CEO Remarks: CEO Roger Jeffs stated that this inclusion is a testament to the team's efforts, reflecting the company's commitment to innovation and operational excellence, with a continued focus on improving care for patients with respiratory and vascular diseases.
- Driving Technological Innovation: Liquidia has developed YUTREPIA® inhalation powder for pulmonary arterial hypertension (PAH) using its proprietary PRINT® technology, and is also developing L606, a new extended-release formulation, showcasing its innovative capabilities in the biopharmaceutical sector.
- Market Outlook: With its inclusion in the small-cap index, Liquidia anticipates attracting more investor attention, potentially driving its market capitalization and long-term value creation, thereby strengthening its position in the highly competitive biopharmaceutical market.
See More
uniQure Achieves Major Regulatory Milestone for Gene Therapy
- Stock Surge: uniQure's shares soared 78.4% on June 17 following the announcement of a major regulatory milestone for AMT-130, although a 3.9% drop on June 18 indicates some volatility; overall, investor confidence in the therapy appears to be strengthening.
- FDA Meeting Outcomes: During a recent Type B meeting, the FDA confirmed that three-year data from the AMT-130 study could serve as the primary basis for a Biologics License Application (BLA), which is expected to be filed in Q3 2026, potentially accelerating market access for the therapy.
- Clinical Trial Design Adjustments: The FDA has requested that uniQure align on the confirmatory study design before BLA submission, including the consideration of a standard-of-care control group, which will impact future clinical trial strategies and timelines.
- Significant Market Potential: As the first therapy for Huntington's disease to receive FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, AMT-130's potential approval could significantly enhance uniQure's market position, addressing a substantial unmet need in Huntington's disease treatment and presenting considerable commercial opportunities for the company.
See More
Beam Therapeutics Receives FDA Clearance for Gene-Editing Therapy
- FDA Approval Milestone: Beam Therapeutics received FDA clearance for its BEAM-304 gene-editing therapy, marking a significant advancement in the liver-targeted genetic disease space, which is expected to enhance its competitiveness in the rare disease market.
- Significant Treatment Potential: BEAM-304 aims to correct mutations in the PAH gene responsible for phenylketonuria (PKU) by lowering toxic phenylalanine levels, potentially allowing patients to maintain a normal diet and reducing reliance on specialized medical foods, which could have a profound market impact.
- Clinical Trial Plans: Beam plans to conduct a Phase I/II open-label clinical study in PKU patients to assess the safety and tolerability of BEAM-304, which is expected to provide critical data for the clinical application of gene-editing therapies and drive future treatment options.
- Strong Stock Performance: Year-to-date, Beam Therapeutics' stock has risen 23.2%, significantly outperforming the biotechnology sector, reflecting positive market expectations for its new therapy and increased investor confidence.
See More
Mirum and Incyte Report Positive Results for FOP Study
- Clinical Trial Results: Mirum and Incyte's Phase II PROGRESS study of zilurgisertib showed that only 3.1% of patients developed new lesions compared to 16.7% in the placebo group, achieving an 81% reduction, indicating the drug's potential in treating this ultra-rare disease.
- Sustained Efficacy: In the open-label extension phase, no new lesions were observed among patients continuing zilurgisertib treatment at 48 weeks, with total lesion volume continuing to decline, demonstrating the drug's long-term efficacy and safety, addressing the urgent need for effective treatments.
- FDA Priority Review: Following positive clinical data, the FDA has accepted the NDA for zilurgisertib and granted Priority Review status, with a decision expected by September 26, 2026, which will expedite the drug's market entry to meet the demand for new therapies.
- Market Performance: Year-to-date, shares of Mirum and Incyte have risen by 28.5% and 1%, respectively, against a 1.4% decline in the biotech sector, reflecting investor optimism regarding their clinical advancements and enhancing their competitive position in the market.
See More
Liquidia Corp Stock Surpasses Analyst Target Price
- Stock Performance: Liquidia Corp's shares recently rose to $71.72, surpassing the average analyst 12-month target price of $66.12, indicating increased market confidence and potentially attracting more investor interest.
- Analyst Reactions: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target; currently, Liquidia's target prices range from $59.00 to $75.00, reflecting varying expectations about the company's future performance.
- Market Signal: The stock's breach of the target price provides a strong signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it’s time to take profits to mitigate risk.
- Analyst Ratings: The average rating for Liquidia Corp within the Zacks coverage universe ranges from 1 to 5, with 1 being a Strong Buy and 5 a Strong Sell, highlighting the differing opinions among analysts regarding the company's future outlook.
See More
Liquidia Presents Research at PHA 2026 Conference
- Research Presentation: Liquidia will present four posters at the 2026 PHA International Conference, highlighting patient-reported cough outcomes from the ASCENT study of YUTREPIA®, demonstrating the company's commitment to pulmonary hypertension patients.
- Patient Feedback Analysis: The posters will showcase cough outcomes in patients with pulmonary hypertension associated with interstitial lung disease over 24 weeks of treatment, providing insights that could influence future treatment strategies.
- Care Team Role Exploration: Liquidia will also discuss the role of pharmacists within pulmonary hypertension care teams and the mental health challenges faced by caregivers, aiming to enhance support for patients and their families.
- Safety and Efficacy Data Review: The company will reiterate safety and exploratory efficacy data from the ASCENT study, further solidifying the potential application of YUTREPIA® in treating pulmonary hypertension.
See More
Liquidia Corporation to Join S&P SmallCap 600 Index
- Index Inclusion Milestone: Liquidia Corporation announced its inclusion in the S&P SmallCap 600 Index effective June 22, 2026, marking a significant advancement in market capitalization, liquidity, and profitability, which is expected to enhance its visibility and attractiveness among investors.
- Positive CEO Remarks: CEO Roger Jeffs stated that this inclusion is a testament to the team's efforts, reflecting the company's commitment to innovation and operational excellence, with a continued focus on improving care for patients with respiratory and vascular diseases.
- Driving Technological Innovation: Liquidia has developed YUTREPIA® inhalation powder for pulmonary arterial hypertension (PAH) using its proprietary PRINT® technology, and is also developing L606, a new extended-release formulation, showcasing its innovative capabilities in the biopharmaceutical sector.
- Market Outlook: With its inclusion in the small-cap index, Liquidia anticipates attracting more investor attention, potentially driving its market capitalization and long-term value creation, thereby strengthening its position in the highly competitive biopharmaceutical market.
See More
